Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 27 January
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia 15 January
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue 12 January
